First generic EpiPen enters the market at half the cost

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/carriecaptured)
(Image: Getty/carriecaptured)

Related tags: EpiPen, Price, competition, Market, allergy, Teva, Mylan

Teva’s EpiPen generic will reach market at a cost of $300 per pack, which matches the price of Mylan’s own generic version.

Mylan’s brand name EpiPen (epinephrine) auto-injector is twice the cost of both generics, with a $600 (€527) price tag. Teva and Mylan’s epinephrine auto-injector generics both retail at $300 for a pack of two.

Teva’s product will be available in limited supply in the US upon launch. The Israeli generics firm has not stated the quantity of supply it intends to introduce onto the market.

Manufacturing of Teva’s product began in August 2018, following its US Food and Drug Administration (FDA) approval. The company stated that additional supply is inbound next year.

Upon US approval of Teva’s product​, FDA commissioner Scott Gottlieb stated, “Today’s approval of the first generic version of the most-widely prescribed epinephrine auto-injector in the US is part of our longstanding commitment to advance access to lower cost, safe and effective generic alternatives.”

Teva’s epinephrine injector will become the first generic EpiPen​ to reach the market, aside from Mylan’s own.

Demand for competition

The release of Teva’s generic comes after supply shortages of EpiPen products had an impact in North America and other regions around the world, as low levels of supply led regulatory authorities to extend expiration dates of the treatment.

Mylan stated​ that the shortages were related to manufacturing issues at a plant run by Meridian Medical technologies, a subsidiary of Pfizer.

Calls for competition have also been issued regarding pricing; In 2016, US Committee on Energy and Commerce expressed concerns about the lack of generic​ competition to Mylan’s product. The issue arose after the drugmaker increased the price of the EpiPen product by a total of 548% between 2007 and 2016.

While Teva’s product will be the first generic of the EpiPen, aside from Mylan’s, other generic epinephrine injector alternatives have reached the market. Kaleo re-launched its Auvi-Q product​, in 2016, and Adamis received approval​ for its Sympjepi equivalent, in 2017.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Related suppliers

Follow us

Products

View more